3 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
Follow Tecfidera: new trials by email Literature Review of Tecfidera trials Research Report on Tecfidera
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants Dimethyl Fumarate, Peginterferon Beta-1a, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Terminated | Biogen | 11 | 2019-03-19 | 2023-06-15 |
| BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis dimethyl fumarate, Placebo - Multiple Sclerosis, Secondary Progressive | Phase 3 | Terminated | Biogen | 58 | 2015-05-01 | 2017-04-26 |
| Tecfidera Slow-Titration Study dimethyl fumarate - Multiple Sclerosis | Phase 3 | Terminated | Biogen | 62 | 2015-04-01 | 2017-05-05 |
Multiple Sclerosis (2) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Biogen (3)
United States (3) · Belgium (2) · Czechia (2) · Colombia (1) · Estonia (1) · Hungary (1) · Italy (1) · Jordan (1) · Malaysia (1) · Mexico (1) · Netherlands (1) · Poland (1) · Saudi Arabia (1) · Slovakia (1) · South Korea (1)
2014 (2), 2018 (1)